c-MET (D1228G)

MET · Variant type: point · HGVS: p.D1228G

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	88.9%	11.1%	88.97
2	Capmatinib	63.4%	36.6%	99.75
3	Tivozanib	59.4%	40.6%	92.42
4	Pacritinib	57.2%	42.8%	88.64
5	Canertinib	53.5%	46.5%	96.49
6	Repotrectinib	51.0%	49.0%	84.21
7	Tepotinib	50.0%	50.0%	99.75
8	Defactinib	45.2%	54.8%	92.68
9	Neratinib	40.5%	59.5%	93.18
10	Vandetanib	38.0%	62.0%	95.74
11	Sunitinib	25.9%	74.1%	91.73
12	Palbociclib	24.6%	75.4%	98.75
13	Selpercatinib	22.8%	77.2%	96.72
14	Pirtobrutinib	19.6%	80.4%	99.49
15	Quizartinib	18.4%	81.6%	99.50
16	Erlotinib	18.1%	81.9%	99.75
17	Fedratinib	18.0%	82.0%	96.21
18	Abemaciclib	14.0%	86.0%	91.48
19	Acalabrutinib	10.4%	89.6%	99.50
20	Sorafenib	10.0%	90.0%	96.72
21	Cobimetinib	8.9%	91.1%	100.00
22	Tenalisib	8.9%	91.1%	97.98
23	Rabusertib	7.9%	92.1%	98.74
24	Ripretinib	7.3%	92.7%	92.95
25	Selumetinib	5.8%	94.3%	100.00

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	88.9%	—	—
Capmatinib	63.4%	—	—
Tivozanib	59.4%	—	—
Pacritinib	57.2%	—	—
Canertinib	53.5%	—	—
Repotrectinib	51.0%	—	—
Tepotinib	50.0%	—	—
Defactinib	45.2%	—	—
Neratinib	40.5%	—	—
Vandetanib	38.0%	—	—
Sunitinib	25.9%	—	—
Palbociclib	24.6%	—	—
Selpercatinib	22.8%	—	—
Pirtobrutinib	19.6%	—	—
Quizartinib	18.4%	—	—
Erlotinib	18.1%	—	—
Fedratinib	18.0%	—	—
Abemaciclib	14.0%	—	—
Acalabrutinib	10.4%	—	—
Sorafenib	10.0%	—	—
Cobimetinib	8.9%	—	—
Tenalisib	8.9%	—	—
Rabusertib	7.9%	—	—
Ripretinib	7.3%	—	—
Selumetinib	5.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.3ms